Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CanSino Biologics Inc.
  6. Company
    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Number of employees : 733 people.
Sales per Business
20192020Delta
Human Vaccine--27.97134.2%-
HKD in Million
Sales per region
20192020Delta
China--27.97134.2%-
HKD in Million
Managers
Name Title Age Since
Xue Feng Yu Chairman, Chief Executive Officer & GM 57 2009
Xi Luo Chief Financial Officer 43 2021
Tao Zhu Executive Director, CSO & Deputy General Manager 47 2009
Jun Qiang Li Senior Director-Research & Development - -
Shou Bai Chao COO, Executive Director & Deputy General Manager 58 2018
Shiu Kwan Wai Independent Non-Executive Director 57 2018
Zhu Xin Independent Non-Executive Director 51 2018
Shui Fa Gui Independent Non-Executive Director 55 2019
Jian Zhong Liu Independent Non-Executive Director 56 2019
Jin Cui Joint Secretary 33 2021
Members of the board
Name Title Age Since
Xue Feng Yu Chairman, Chief Executive Officer & GM 57 2009
Jiang Feng Li Chairman-Supervisory Board 43 2019
Tao Zhu Executive Director, CSO & Deputy General Manager 47 2009
Dong Xu Qiu Executive Director & Deputy General Manager 60 2009
Zhong Qi Shao, Dr. Member-Supervisory Board & VP-Vaccine Research - 2021
Shou Bai Chao COO, Executive Director & Deputy General Manager 58 2018
Liang Lin Non-Executive Director 46 2013
Shiu Kwan Wai Independent Non-Executive Director 57 2018
Zhu Xin Independent Non-Executive Director 51 2018
Zheng Fang Liao Member-Supervisory Board 35 2016
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 132,670,900 97,881,429 73.8% 0 0.0% 37.1%
Stock B 0 114,778,999 0 0.0% 0 0.0%
Stock C 0 16,724,200 0 0.0% 0 0.0%
Shareholders
NameEquities%
Capital Research & Management Co. (Global Investors) 12,703,835 9.58%
LAV Management Co., Ltd. 12,585,562 9.49%
Hui Hua Mao 11,924,700 8.99%
Xue Feng Yu 11,590,183 8.74%
Dong Xu Qiu 11,083,517 8.35%
Capital Research & Management Co. (World Investors) 10,972,122 8.27%
OrbiMed Advisors Private Equity 7,967,600 6.01%
Qiming Venture Partners Ltd. 7,516,538 5.67%
The Vanguard Group, Inc. 2,568,236 1.94%
BlackRock Fund Advisors 1,703,600 1.28%
Company contact information
CanSino Biologics, Inc.
4/F, Room 401-420, Biomedical Park
No. 185 South Street
TEDA West District
Tianjin 300457

Phone : +86.22.58213766
Fax : +86.22.58213626
Web : http://www.cansinotech.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of CanSino Biologics Inc.